Every weekday, CNBC Investing Club with Jim Cramer publishes Homestretch – an actionable afternoon update just in time for the ultimate hour of trading on Wall Street. Markets: Wall Street rose sharply on Wednesday because of the week's second encouraging inflation report and a string of strong bank earnings. The consumer price index (excluding food and energy) was barely below expectations before the opening bell on Wednesday, a day after a measure of wholesale inflation did the identical. The likelihood that the Federal Reserve will cut rates of interest twice this yr has increased following Wednesday's release of the buyer price index, in accordance with the CME FedWatch tool. The hot December jobs report released on Friday had investors rethinking the long run rate cut path. Financials were certainly one of 4 of 11 sectors within the S&P 500 to realize greater than 2% on Wednesday. Communications services, consumer discretionary and technology are the others. Earnings reports drove developments within the financial sector. Club name BlackRock rose about 5% after its results showed recent sellers had jumped ship too early. Wall Street properly focused on the larger picture, together with portfolio peer Wells Fargo, sending its shares up 7%. Meanwhile, Goldman Sachs confirmed our recent move out of Morgan Stanley as executives expressed optimism about business activity in 2025. Bristol Vision: The biggest marketplace for Bristol Myers Squibb's latest schizophrenia treatment could actually be patients with Alzheimer's disease. That's what business leaders said after they spoke with our CNBC colleague Annika Kim Constantino on the JPMorgan Healthcare Conference in San Francisco. Here is an excerpt from her story. In an interview, company executives said each treatment use they’re exploring for Cobenfy has multibillion-dollar potential, including Alzheimer's psychosis, Alzheimer's agitation and cognition, bipolar disease and autism. But Alzheimer's is the “really big market” here, Bristol Myers Squibb CFO David Elkins told CNBC. … There are nearly 6 million patients with Alzheimer's disease within the United States, and about half of them suffer from psychosis or symptoms similar to hallucinations and delusions, Elkins said. Cobenfy could possibly be the primary drug approved specifically for Alzheimer's-related psychosis, said Adam Lenkowsky, chief commercialization officer. Cobenfy's long-term potential is central to our investment thesis in Bristol Myers, and its opportunities in areas beyond schizophrenia feed into our optimism. Jim Cramer said that Cobenfy's annual sales could someday reach $10 billion, considering all possible uses. We'll be keeping track of the outcomes of Bristol Myers' late-stage study on Alzheimer's-related psychosis, now expected to be published later this yr. Shares of Bristol Myers rose barely on Wednesday. Portfolio peer Eli Lilly can be involved within the Alzheimer's treatment market, but otherwise. Lilly's Kisunla, approved by U.S. regulators last yr, is designed to slow the actual progression of the memory-robbing disease by removing abnormal protein clumps within the brains of Alzheimer's patients. The drug's market launch has been slow. Biotech exports: Club names GE Healthcare and Danaher gave up early gains on Wednesday after news that the Commerce Department is imposing latest controls on exports of biotech equipment to China. Citing national security concerns, the agency said the biotechnology tools could possibly be used for “improving human performance, for brain-machine interfaces, for biologically inspired synthetic materials and potentially for biological weapons.” Research analysts at Leerink said Wednesday the rule “appears to be narrow.” That could limit the impact on Danaher. Additionally, Danaher can deploy almost its entire portfolio locally in China, which should help the corporate navigate controls. We don't think GE Healthcare is selling any products related to this decision, however the stock still fell in sympathy. Additionally, the corporate has a robust manufacturing presence in China. The latest biotech export rules are a part of the Biden administration's broader technique to limit the flow of cutting-edge American technology to China. The White House fears that access to such technology could possibly be utilized by the Chinese government to strengthen its military capabilities. On Monday, the Commerce Department also proposed latest restrictions on AI chip exports, impacting portfolio stock Nvidia in back-to-back meetings. However, Nvidia shares rose 3% on Wednesday, breaking a five-day losing streak. China Update: Before the export decision was announced, GEHC shares opened higher on Wednesday, the morning after what we might describe as a sigh of relief from management in its presentation on the JPMorgan Healthcare Conference. The key takeaway: China is performing barely higher than expected and there are signs of increased activity. While there could also be signs of a rebound, guidance stays low and management has been cautious about keeping expectations low by once more exercising caution. Jeff Marks, director of portfolio evaluation at Investing Club, said on Wednesday he was glad business on this planet's second-largest economy was not deteriorating because it awaited promised stimulus from the Chinese government. Next up: Following strong quarterly results from our three portfolio financial corporations, banking results proceed Thursday morning with Bank of America and Morgan Stanley. We'll be on the lookout for Nvidia and Broadcom stocks in Taiwan Semiconductor Manufacturing Company's premarket earnings. In addition to the earnings, the federal government's December retail sales figure can be released at 8:30 a.m. ET. Although not adjusted for inflation, we'll see how shoppers felt over the ultimate month of the vacation shopping season, given the cooler consumer inflation trends outlined Wednesday morning. (A whole list of Jim Cramer's Charitable Trust stocks will be found here.) As a subscriber to CNBC Investing Club with Jim Cramer, you’ll receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable foundation's portfolio. If Jim discussed a stock on CNBC television, he waits 72 hours after the trade alert is issued before executing the trade. THE INVESTING CLUB INFORMATION SET FORTH ABOVE IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY, ALONG WITH OUR DISCLAIMER. THERE ARE NO fiduciary duty or duty IN RECEIVING YOUR INFORMATION PROVIDED IN CONNECTION WITH THE INVESTMENT CLUB. NO SPECIFIC RESULTS OR PROFITS ARE GUARANTEED.
image credit : www.cnbc.com